Cargando…

Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-target...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiraishi, Keizo, Kurahara, Lin Hai, Ishikawa, Kaori, Go, Tetsuhiko, Yokota, Naoya, Hu, Yaopeng, Fujita, Takayuki, Inoue, Ryuji, Hirano, Katsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Society of Smooth Muscle Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364263/
https://www.ncbi.nlm.nih.gov/pubmed/35944979
http://dx.doi.org/10.1540/jsmr.58.50
_version_ 1784765112441110528
author Hiraishi, Keizo
Kurahara, Lin Hai
Ishikawa, Kaori
Go, Tetsuhiko
Yokota, Naoya
Hu, Yaopeng
Fujita, Takayuki
Inoue, Ryuji
Hirano, Katsuya
author_facet Hiraishi, Keizo
Kurahara, Lin Hai
Ishikawa, Kaori
Go, Tetsuhiko
Yokota, Naoya
Hu, Yaopeng
Fujita, Takayuki
Inoue, Ryuji
Hirano, Katsuya
author_sort Hiraishi, Keizo
collection PubMed
description Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-targeted therapeutics centered on pulmonary artery relaxants. It is necessary to identify the target molecules that contribute to pulmonary artery remodeling. Transient receptor potential (TRP) channels have been suggested to modulate pulmonary artery remodeling. Our study focused on the transient receptor potential ion channel subfamily M, member 7, or the TRPM7 channel, which modulates endothelial-to-mesenchymal transition and smooth muscle proliferation in the pulmonary artery. In this review, we summarize the role and expression profile of TRPM7 channels in PAH progression and discuss TRPM7 channels as possible therapeutic targets. In addition, we discuss the therapeutic effect of a Chinese herbal medicine, Ophiocordyceps sinensis (OCS), on PAH progression, which partly involves TRPM7 inhibition.
format Online
Article
Text
id pubmed-9364263
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japan Society of Smooth Muscle Research
record_format MEDLINE/PubMed
spelling pubmed-93642632022-08-29 Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension Hiraishi, Keizo Kurahara, Lin Hai Ishikawa, Kaori Go, Tetsuhiko Yokota, Naoya Hu, Yaopeng Fujita, Takayuki Inoue, Ryuji Hirano, Katsuya J Smooth Muscle Res Invited Review Pulmonary arterial hypertension (PAH) is an intractable vascular disease characterized by a progressive increase in pulmonary vascular resistance caused by pulmonary vascular remodeling, which ultimately leads to right-sided heart failure. PAH remains incurable, despite the development of PAH-targeted therapeutics centered on pulmonary artery relaxants. It is necessary to identify the target molecules that contribute to pulmonary artery remodeling. Transient receptor potential (TRP) channels have been suggested to modulate pulmonary artery remodeling. Our study focused on the transient receptor potential ion channel subfamily M, member 7, or the TRPM7 channel, which modulates endothelial-to-mesenchymal transition and smooth muscle proliferation in the pulmonary artery. In this review, we summarize the role and expression profile of TRPM7 channels in PAH progression and discuss TRPM7 channels as possible therapeutic targets. In addition, we discuss the therapeutic effect of a Chinese herbal medicine, Ophiocordyceps sinensis (OCS), on PAH progression, which partly involves TRPM7 inhibition. Japan Society of Smooth Muscle Research 2022-08-10 2022 /pmc/articles/PMC9364263/ /pubmed/35944979 http://dx.doi.org/10.1540/jsmr.58.50 Text en ©2022 The Japan Society of Smooth Muscle Research https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Invited Review
Hiraishi, Keizo
Kurahara, Lin Hai
Ishikawa, Kaori
Go, Tetsuhiko
Yokota, Naoya
Hu, Yaopeng
Fujita, Takayuki
Inoue, Ryuji
Hirano, Katsuya
Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
title Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
title_full Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
title_fullStr Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
title_full_unstemmed Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
title_short Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension
title_sort potential of the trpm7 channel as a novel therapeutic target for pulmonary arterial hypertension
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364263/
https://www.ncbi.nlm.nih.gov/pubmed/35944979
http://dx.doi.org/10.1540/jsmr.58.50
work_keys_str_mv AT hiraishikeizo potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT kuraharalinhai potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT ishikawakaori potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT gotetsuhiko potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT yokotanaoya potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT huyaopeng potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT fujitatakayuki potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT inoueryuji potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension
AT hiranokatsuya potentialofthetrpm7channelasanoveltherapeutictargetforpulmonaryarterialhypertension